Clover Health Investments AI Stock Analysis
Want to see CLOV full AI Analyst Report?
Clover Health Investments (CLOV) AI Stock Analysis
Clover Health Investments
(NASDAQ:CLOV)
The score is driven primarily by improving financial performance (turnaround to positive TTM earnings, strong cash-flow rebound, and no debt) and a bullish, guidance-raising earnings call that supports continued growth and profitability. These positives are tempered by a demanding valuation (very high P/E) and only mixed technical momentum signals.
Clover Health Investments Key Performance Indicators (KPIs)
Revenue by SegmentSeparates revenue into lines like Medicare Advantage premiums versus platform or services revenue. Identifies which activities drive top-line growth and which deliver higher margins. A shift toward service or platform revenue can improve profitability and diversify risk, whereas dependence on premium revenue makes results more sensitive to medical costs and regulatory changes.
Clover has shifted from a mix of non‑insurance and premium revenue to being overwhelmingly premium‑driven: Non‑Insurance Revenue collapsed to zero after 2023 (likely one‑offs or discontinued activities), while Premiums Earned surged in 2025, signaling membership/market share growth. That improves top‑line predictability but concentrates risk on medical cost trends and Medicare policy/underwriting performance. The small, volatile “Other” line (notably the Sept‑2025 spike) looks like a one‑time item—track margins and guidance to judge whether higher premiums convert to durable profit.
Clover Health Investments (CLOV) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.63B
- Dividend Yield
- ―
- Average Volume (3M)
- 4.26M
- Price to Earnings (P/E)
- 289.1
- Beta (1Y)
- 1.44
- Revenue Growth
- 54.46%
- EPS Growth
- ―
- Country
- US
- Employees
- 724
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Plans
Clover Health Investments Business Overview & Revenue Model
Company Description
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Mainte...
How the Company Makes Money
Clover Health primarily makes money by operating Medicare Advantage (MA) plans and earning premium revenue that is largely funded by the U.S. government (Centers for Medicare & Medicaid Services, CMS). For each enrolled member, Clover receives a per-...
Clover Health Investments Earnings Call Summary
The call was strongly positive, with substantial membership, revenue, gross profit, EBITDA and net income growth; improved full-year guidance; expected first full-year GAAP profitability; leading Star Ratings and HEDIS performance; favorable cohort economics; and encouraging early 2027 enrollment results. The company also identified meaningful earnings expansion opportunities from cohort maturation and operating leverage. Offsetting issues included elevated outpatient utilization, a planned seasonal fourth-quarter EBITDA loss, a near-term earnings drag from new members, a pending government appeal and management's criticism of the current Stars measurement framework.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, Clover expects average Medicare Advantage membership of 157,000 to 158,000 members, total revenue of $2.97 billion to $3 billion, consolidated gross profit of $540 million to $555 million, adjusted EBITDA of $75 million to $85 million and GAAP net income of $25 million to $35 million; for the full year, it expects adjusted SG&A ratio improvement at or above its original target of 100 basis points to 150 basis points, while the fourth quarter is expected to include lower consolidated gross profit from normal medical cost seasonality, higher SG&A as planned AEP investments increase and the seasonal adjusted EBITDA loss already contemplated in guidance. Clover is not providing formal guidance for 2027 or 2028, but expects another strong year of membership growth, meaningful earnings expansion in 2027 and momentum into 2028, with insurance gross profit per member per month approximately $70 higher in year 2 than in year 1 and approximately $85 higher in year 3 than in year 2; approximately half of current membership comprises the 2025 and 2026 cohorts, with 21% of members in their second year this year and 28% in year 1.
Clover Health Investments Financial Statement Overview
Summary
Financials reflect a clear turnaround: strong TTM revenue growth (10.6%), a move to modest TTM net income (~$12.5M), zero debt with rebuilding equity, and a sharp rebound in operating/free cash flow (OCF ~$135.3M; FCF ~$132.3M). The main constraint is durability—net margins are still very thin and cash flows have been historically volatile, leaving results sensitive to medical-cost and expense swings.
Income Statement
62PositiveBalance Sheet
70PositiveCash Flow
73Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.74B | 1.92B | 1.37B | 1.26B | 1.10B | 1.47B |
| Gross Profit | 516.60M | 355.88M | 364.80M | 255.95M | 103.48M | -79.18M |
| EBITDA | 14.56M | -83.86M | -44.94M | -207.63M | -252.03M | -569.60M |
| Net Income | 12.45M | -85.55M | -43.01M | -213.36M | -339.57M | -587.76M |
Balance Sheet | ||||||
| Total Assets | 753.68M | 541.01M | 580.74M | 570.67M | 808.62M | 950.80M |
| Cash, Cash Equivalents and Short-Term Investments | 272.58M | 95.35M | 221.54M | 242.69M | 334.76M | 615.25M |
| Total Debt | 0 | 0 | 0 | 4.66M | 5.86M | 27.83M |
| Total Liabilities | 362.81M | 232.31M | 239.60M | 284.28M | 451.73M | 411.49M |
| Stockholders Equity | 390.87M | 308.70M | 341.14M | 286.39M | 356.89M | 535.41M |
Cash Flow | ||||||
| Free Cash Flow | 132.28M | -68.98M | 33.29M | -116.45M | -208.39M | -283.05M |
| Operating Cash Flow | 135.31M | -66.93M | 34.84M | -115.87M | -203.93M | -282.33M |
| Investing Cash Flow | -42.97M | 4.08M | 565.00K | 140.01M | 95.13M | -435.45M |
| Financing Cash Flow | -14.33M | -53.38M | -17.36M | -33.86M | -4.96M | 925.39M |
Clover Health Investments Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLOV, the sentiment is Positive. The current price of 4.95 is above the 20-day moving average (MA) of 4.70, above the 50-day MA of 4.62, and above the 200-day MA of 3.67, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 58.28 is Neutral, neither overbought nor oversold. The STOCH value of 66.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLOV.
Clover Health Investments Risk Analysis
Clover Health Investments disclosed 67 risk factors in its most recent earnings report. Clover Health Investments reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksClover Health Investments Peers Comparison
Overall Rating
ELV76Outperform
CLOV67Neutral
CNC66Neutral
UNH62Neutral
ALHC60Neutral
HUM58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | $96.42B | 18.97 | 11.59% | 1.54% | 3.60% | -4.06% | |
| 67Neutral | $2.63B | 289.12 | 3.52% | ― | 54.46% | ― | |
| 66Neutral | $37.02B | 25.26 | 6.78% | ― | 9.71% | ― | |
| 62Neutral | $369.18B | 23.39 | 16.35% | 2.20% | 3.33% | -8.75% | |
| 60Neutral | $1.56B | 52.45 | 12.46% | ― | 35.87% | ― | |
| 58Neutral | $55.40B | 44.41 | 6.70% | 0.77% | 22.02% | -3.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CLOV | Clover Health Investments Corp | 4.95 | 2.60 | 110.64% | |
| CNC | Centene | 74.77 | 37.84 | 102.46% | |
| HUM | Humana | 461.25 | 230.17 | 99.60% | |
| UNH | Unitedhealth Group Inc. | 412.02 | 106.57 | 34.89% | |
| ELV | Elevance Health, Inc. | 446.28 | 128.08 | 40.25% | |
| ALHC | Alignment Healthcare, Inc. | 7.47 | -8.63 | -53.60% |
Clover Health Investments Corporate Events
Clover Health Releases Supplemental Shareholder Q&A Responses
NeutralOn November 16, 2026, Clover Health published supplemental responses to selected shareholder questions submitted in connection with its third-quarter 2026 earnings announcement. The Q&A addressed the company’s business scale, operating expenses, Coun...
Clover Health Reports Strong Third-Quarter Results and Growth
PositiveOn November 2, 2026, Clover’s board appointed interim Chief Financial Officer Clay Thornton to the position permanently and named Vice President and Controller Joseph Oldakowski chief accounting officer, effective November 4. Their new agreements pro...
Clover Health Earns Top CMS Star Ratings for 2027
PositiveOn October 8, 2026, Clover Health announced that the Centers for Medicare & Medicaid Services awarded its PPO Medicare Advantage plans a 5-Star rating and its HMO plan a 4.5-Star rating for the 2027 measurement year, which will drive 2028 payment lev...
Clover Health Adds Policy and Clinical Experts to Board
PositiveOn September 22, 2026, Clover Health Investments appointed former U.S. Senator Robert G. Torricelli and MedPAC Commissioner Dr. Brian J. Miller to its Board of Directors, filling two previously disclosed vacancies and expanding the Board to nine memb...
Clover Health Highlights Depth-Focused Strategy and Technology Investments
PositiveOn August 20, 2026, Clover Health released a supplemental Q&A tied to its second-quarter 2026 earnings, aiming to deepen engagement with shareholders and clarify its operating model and outlook. Management highlighted how its Clover Assistant-driven...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
